4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.
May 2025 in “Frontiers in Immunology” This paper discusses the balance between target tissue destruction and recovery rates in autoimmune diseases, proposing that high recovery rates are crucial for remitting-relapsing patterns, while exercise might not be neuroprotective in secondary progressive multiple sclerosis.
November 2025 in “Indian Journal of Nephrology” In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.
13 citations
,
August 2000 in “Blood” This article discusses the evaluation of minimal residual disease in childhood acute lymphoblastic leukemia using molecular methods and reports no new findings.
1 citations
,
December 2012 in “Journal of the European Academy of Dermatology and Venereology” This letter to the editor reports that sentinel lymph node status is the strongest independent predictor for both disease-free and overall survival in patients with thick melanoma.
